Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung

Anticancer Res. 2009 May;29(5):1817-22.

Abstract

Background: The frequency of epithelial cell adhesion molecule (EpCAM) expression was investigated in non-small cell lung cancer (NSCLC) cells and human tissues, and its clinicopathological significance in adenocarcinoma of the lung was evaluated.

Materials and methods: EpCAM expression was analysed by reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometry in human NSCLC cells. EpCAM protein expression was evaluated in 234 adenocarcinoma tissues using immunohistochemistry.

Results: A high expression level of EpCAM was observed in human NSCLC cells by flow cytometry and RT-PCR. EpCAM overexpression was detected in 120/234 (51.3%) surgically resected adenocarcinoma tissues. EpCAM overexpression occurred significantly more frequently in adenocarcinoma than in bronchioloalveolar carcinoma (p=0.02). The overall survival did not differ significantly between EpCAM-overexpressing and EpCAM-negative patients (p=0.40).

Conclusion: These findings suggest EpCAM plays a role in the carcinogenesis of adenocarcinoma of the lung and might provide a promising molecule for targeted therapy in NSCLC.

MeSH terms

  • Adenocarcinoma / metabolism*
  • Adenocarcinoma / pathology
  • Antigens, Neoplasm / metabolism*
  • Base Sequence
  • Cell Adhesion Molecules / metabolism*
  • Cell Line, Tumor
  • DNA Primers
  • Epithelial Cell Adhesion Molecule
  • Flow Cytometry
  • Humans
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / pathology
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • Antigens, Neoplasm
  • Cell Adhesion Molecules
  • DNA Primers
  • EPCAM protein, human
  • Epithelial Cell Adhesion Molecule